The Complexity of Sporadic Alzheimer’s Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia. Amyloid plaques and neurofibrillary tangles are prominent pathological features of AD. Aging and age-dependent oxidative stress are the major nongenetic risk factors for AD. The beta-amyloid peptide (Aβ), the major component of plaques, and advanced glycation end products (AGEs) are key activators of plaque-associated cellular dysfunction. Aβ and AGEs bind to the receptor for AGEs (RAGE), which transmits the signal from RAGE via redox-sensitive pathways to nuclear factor kappa-B (NF-κB). RAGE-mediated signaling is an important contributor to neurodegeneration in AD. We will summarize the current knowledge and ongoing studies on RAGE function in AD. We will also present evidence for a novel pathway induced by RAGE in AD, which leads to the expression of thioredoxin interacting protein (TXNIP), providing further evidence that pharmacological inhibition of RAGE will promote neuroprotection by blocking neurovascular dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 3×
“The expression level of RAGE is high in rodent cortical neurons during the neonatal period [49], while its presence strongly decreases during maturity with few cortical neurons showing RAGE staining [50].”
BackgroundSelf-citationHarman, D. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.7124 · Cited by 1,915
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“These mice show Aβ-induced synaptotoxicity in the absence of amyloid plaque [55].”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Self-citationUnderstanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 7×
“subsequent oxidative stress and inflammation, which in turn sustain the formation of AGEs and Aβ [17].”
BackgroundSelf-citationEpidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
NF-κB in neuronal plasticity and neurodegenerative disorders
Mattson, M. P., & Camandola, S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11916 · Cited by 877 · cited 1×
“Activation of NF-κB and induction of cytokines can also contribute to neuronal plasticity and the cellular response to neurodegeneration [48].”
BackgroundAdvanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806 · cited 1×
“accelerate Aβ deposition [14, 15].”
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524 · cited 8×
“The combination of AGEs and Aβ synergistically induces the expression of proinflammatory cytokines, such as TNF-α, IL-6, and M-CSF [45].”
BackgroundInfluentialSynaptic NMDA receptor activity boosts intrinsic antioxidant defenses
Papadia, S., Soriano, F. X., Léveillé, F., Martel, M.-A., Dakin, K. A., Hansen, H. H., Kaindl, A., Sifringer, M., Fowler, J., Stefovska, V., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2071 · Cited by 498 · cited 1×
“Blockade of NMDAR enhances TXNIP expression, promoting neuronal vulnerability to oxidative damage [94].”
BackgroundTXNIP regulates peripheral glucose metabolism in humans
Parikh, H., Carlsson, E., Chutkow, W. A., Johansson, L. E., Storgaard, H., Poulsen, P., Saxena, R., Ladd, C., Schulze, P. C., Mazzini, M. J., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040158 · Cited by 495 · cited 1×
“However, recent studies demonstrated that TXNIP regulates glucose metabolism [88, 89], and its expression is associated to the senescence process [90].”
BackgroundCraft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“Insulin is necessary to maintain normal brain function, and peripheral insulin resistance enhances the risk to develop AD, by affecting brain glucose metabolism, neurotransmitters levels, enhancing inflammation [33].”
BackgroundYan, S. D., Yan, S. F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., et al. (1995) · Nature Medicine · doi:10.1038/nm0795-693 · Cited by 406 · cited 1×
“Indeed, the brain is particularly vulnerable to oxidative damage because of its high utilization of oxygen, increased levels of polyunsaturated fatty acid, and relatively high levels of redox transition metal ions; in addition, the brain has relatively low levels of antioxidants [39].”
BackgroundSelf-citationBlasko, I., Stampfer‐Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., & Grubeck‐Loebenstein, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00101.x · Cited by 374
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351 · cited 1×
“In agreement, Tg2576 AD mice display enhanced BBB permeability compared to control mice at 4 months of age, before the appearance of plaque deposition and memory impairment [81].”
BackgroundFang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335 · cited 4×
“Activated microglia exacerbate Aβ-induced neuronal toxicity [74], and RAGE is a key mediator of activated microglial effects in AD neuronal dysfunction [78, 79].”
BackgroundInfluentialRAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction
Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., Sosunov, A., McKhann, G., Funatsu, Y., Nakamichi, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905686106 · Cited by 290
Faller, P. (2009) · ChemBioChem · doi:10.1002/cbic.200900321 · Cited by 285
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153 · cited 3×
“Since angiogenesis occurs in AD [80], we investigated whether Aβ treatment induces TXNIP translocation in RBE4 cells.”
BackgroundChutkow, W. A., Birkenfeld, A. L., Brown, J. D., Lee, H.-Y., Frederick, D. W., Yoshioka, J., Patwari, P., Kursawe, R., Cushman, S. W., Plutzky, J., et al. (2010) · Diabetes · doi:10.2337/db09-1212 · Cited by 142 · cited 2×
“Interestingly, TXNIP is necessary to mediate insulin resistance in diabetes [34].”
BackgroundHorie, K., Miyata, T., Yasuda, T., Takeda, A., Yasuda, Y., Maeda, K., Sobue, G., & Kurokawa, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6944 · Cited by 137
Origlia, N., Bonadonna, C., Rosellini, A., Leznik, E., Arancio, O., Yan, S. S., & Domenici, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2127-10.2010 · Cited by 111 · cited 2×
“Activated microglia exacerbate Aβ-induced neuronal toxicity [74], and RAGE is a key mediator of activated microglial effects in AD neuronal dysfunction [78, 79].”
BackgroundRAGE Does Not Affect Amyloid Pathology in Transgenic ArcAβ Mice
Vodopivec, I., Galichet, A., Knobloch, M., Bierhaus, A., Heizmann, C. W., & Nitsch, R. M. (2009) · Neurodegenerative Diseases · doi:10.1159/000261723 · Cited by 23 · cited 1×
“In contrast, in Arc/swe AD mice, which overexpress hAPP carrying the Swedish (swe) mutation, which enhances Aβ production, and the arctic (arc) mutation in Aβ sequence, which leads to a faster aggregation of Aβ [60], the knockout of RAGE has only a minimal effect on Aβ load and does not ameliorate synaptic dysfunction.”
BackgroundSelf-citation
Cited by
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Nutrition and AGE‐ing: Focusing on Alzheimer’s Disease
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7039816 · Cited by 103
RAGE-TXNIP axis drives inflammation in Alzheimer’s by targeting Aβ to mitochondria in microglia
Sbai, O., Djelloul, M., Auletta, A., Ieraci, A., Vascotto, C., & Perrone, L. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04758-0 · Cited by 72
“Receptor for advanced glycation end products (RAGE) is a multiligand transmembrane receptor of the immunoglobulin superfamily and is the counterreceptor of proinflammatory ligands, such as advanced glycation endproducts (AGEs), S100s, HMGB1, and Aβ [19].”
BackgroundSelf-citation
Metadata
- Authors
- Perrone, L., Sbai, O., Nawroth, P. P., & Bierhaus, A.
- Venue
- International Journal of Alzheimer's Disease
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-13
- ISSN
- 2090-0252 (ISSN-L)
- 2090-8024
- OpenAlex
- W2001277875
- Cited by
- 51
- References
- 27
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.